Urologic Health in Women Across the Lifespan
Monica P. Mallampalli, PhD, MSc. and Christine L. Carter, PhD, MPH

Goal: Understand the current state of urologic health across the lifespan and obtain expert roundtable recommendations

Background

SWHR routinely convenes interdisciplinary scientific roundtables to address key issues in women’s health. Established investigators are invited for 1.5 days for an in-depth discussion to explore knowledge gaps and novel research opportunities in diseases that predominately or disproportionately affect women. On October 29-30, 2014, SWHR hosted a roundtable on “Understanding urologic health in women across the lifespan.” The goal was to facilitate the understanding of the current state of urologic health across a woman’s lifespan by identifying key knowledge gaps and addressing research opportunities with a focus on preventing urologic diseases in women.

Objectives

- Discuss emerging urologic issues specific to women throughout the various key stages of the lifespan;
- Examine state-of-the-science and identify critical research gaps in the area of epidemiology, basic research, clinical presentation and therapeutic strategies;
- Examine pharmacological and non-pharmacological therapeutic strategies for conditions that affect women throughout the lifespan;
- Address impact of urologic diseases and related comorbid conditions on quality of life in women.

Method

This interdisciplinary meeting included 16 researchers from the following disciplines: urology, urogynecology, pediatrics, gerontology, neurology, biomechanical engineering, regenerative medicine, reconstructive surgery, obstetrics and gynecology, microbiology, immunology, cellular and molecular biology and epidemiology. Participants were assigned to one or two topics. Underlined participant was chosen as the group leader.

A. Epidemiology and Prevention

- Cara Tannenbaum, MD, MSc., University of Montreal
- Roger Dmochowski, MD, Vanderbilt University
- Heidi Harvie, MBA, MD, MSc., University of Pennsylvania
- Leslee Subak, MD, Univ. of California, San Francisco

B. Clinical presentation

- Stephanie Kelb, MD, Northwestern University
- Clare Close, MD, Close Pediatric Urology
- George Kuchel, MD, University of Connecticut
- Elizabeth Mueller, MD, Loyola University
- Candace Parker-Autry, MD, Wake Forest Baptist

C. Biological basis

- Toby Chai, MD, Yale School of Medicine
- Margo Damaser, PhD, Cleveland Clinic
- Michael DiSanto, PhD, Rowan University
- George Kuchel, MD, University of Connecticut
- Alan Wolfe, PhD, Loyola University

D. Current and novel therapeutic strategies

- Matthew Fraser, PhD, Duke University
- Cindy Amundsen, MD, Duke University
- James Ashton-Miller, PhD, University of Michigan
- Margo Damaser, PhD, Cleveland Clinic

A. Epidemiology and Prevention

- 53% of women will have at least one urinary tract infection (UTI) during their lifetime.1
- 25-44% women experience recurrent UTI annually.2
- 24% of women (ages of 18-44) and 50% (ages 45-60) have urinary incontinence (UI).3
- Direct care for UI in 2000 cost $452.8 million for women compared to 10.3 million in men.4


B. Clinical presentation

- No more epidemiology research for incontinence;
- Determine increased healthcare seeking behavior for women with incontinence;
- Develop implementation research to extend reach to incontinence patients;
- Optimize individual adherence to lifestyle changes and prevention strategies for incontinence;
- Develop prevention research for urinary tract infection and chronic pelvic pain.

C. Biological basis

- Understand risk and protective factors around urinary microbiome;
- Determine biological mechanisms for pelvic pain, incontinence, urge incontinence, overactive bladder and pelvic floor disorders;
- Determine sex differences in urethral muscle contribution towards urethral closure;
- Identify predictive biomarkers to distinguish between various types of bladder dysfunction;
- Develop better, complete, chronic animal models to capture risk factors and understand incontinence.

D. Current and novel therapeutic strategies

- Explore novel (cell therapy and regenerative medicine), rational (based on phenotypes) and combination therapeutic approaches;
- Determine drug mechanisms for current and future therapies;
- Determine differential drug response to same drugs by different patients;
- Develop targeted therapy based on phenotyping and disease etiology;
- Develop effective synergistic therapies and optimize parameters for existing therapies such as neuromodulation.

Conclusions

The identification of multiple knowledge gaps and subsequent discussions at the roundtable led to the development of research recommendations.

Understanding basic biological mechanisms will only allow for better diagnosis, treatment and eventually prevention of these disorders in women.

An established program such as the SWHR’s interdisciplinary networks may be the platform needed to address some of these identified research needs in women’s urologic health.

Funding

The roundtable meeting was made possible by generous funding from Astellas, Allegan, Cook Medical, Amphora Medical and Medtronic.

SWHR®

SWHR is a national non-profit organization based in Washington D.C. and founded in 1990. SWHR is widely recognized as the thought leader in research on biological differences in disease and is dedicated to transforming women’s health through science, advocacy and education.